1. Volume 68, Issue 1, Pages 246-255 (July 2005)
Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: Effect of long-term therapy with erythropoietin 
Eleni C. Papavasiliou, Chariklia Gouva, Kostas C. Siamopoulos, Alexandros D. Tselepis 
Kidney International 
Volume 68, Issue 1, Pages (July 2005)
DOI: /j x
Copyright © 2005 International Society of Nephrology Terms and Conditions

2. Figure 1
Baseline values of PAF-AH activity in the cytosolic (A) and the membrane fractions (B) of erythrocytes from CKD patients and controls. PAF-AH activity was determined by the TCA precipitation method. Data are expressed as mean ± SD. *P < 0.05 compared with controls; **P < compared with controls; and$P < 0.05 compared with group I.
Kidney International  , DOI: ( /j x)
Copyright © 2005 International Society of Nephrology Terms and Conditions

3. Figure 2
Correlation between the cytosolic PAF-AH activity and creatinine clearance values in all studied populations.
Kidney International  , DOI: ( /j x)
Copyright © 2005 International Society of Nephrology Terms and Conditions

4. Figure 3
Erythrocyte-associated PAF-AH activity in CKD patients of stages 3 to 5 at baseline and during the follow-up. (A) Cytosolic fraction. (B) Membrane fraction. PAF-AH activity was determined by the TCA precipitation method. Data are expressed as mean ± SD. *P < 0.05 and **P < compared with baseline values.
Kidney International  , DOI: ( /j x)
Copyright © 2005 International Society of Nephrology Terms and Conditions

5. Figure 4
Correlation between the reduction in the PAF-AH activity of the erythrocyte cytosolic fraction and the decrease in creatinine clearance values in CKD patients of stages 3 to 5 not treated with EPO.
Kidney International  , DOI: ( /j x)
Copyright © 2005 International Society of Nephrology Terms and Conditions

6. Figure 5
Erythrocyte-associated Gpx activity (A) in all study populations at baseline and (B) in CKD patients of stages 3 to 5 at baseline and during the follow-up. Gpx activity was determined spectrophotometrically and quantitated by measuring the change in absorbance at 340nm caused by the oxidation of NADPH. One IU is defined as the amount of enzyme that will cause the oxidation of 1.0mmol/L of NADPH to NADP per minute at 37°C measured at 340nm Data are expressed as mean ± SD. *P < 0.05 and **P < compared with controls.$P < 0.05 compared with baseline values of group III.
Kidney International  , DOI: ( /j x)
Copyright © 2005 International Society of Nephrology Terms and Conditions

7. Figure 6
Plasma TBARS levels (A) in all study populations at baseline and (B) in CKD patients of stages 3 to 5 at baseline and during the follow-up. TBARS levels in plasma were determined spectrophotometrically, and expressed as nmol of malondialdehyde (MDA) equivalents/mL of plasma. Data are expressed as mean ± SD. *P < 0.05 compared with either controls or group I.
Kidney International  , DOI: ( /j x)
Copyright © 2005 International Society of Nephrology Terms and Conditions

8. Figure 7
Effects of Cu2+-induced oxidation of erythrocytes in the presence or absence of EPO in vitro. (A) Oxidation-induced erythrocyte lysis and (B) oxidation-induced reduction in PAF-AH and Gpx activities. Oxidation of washed erythrocytes was performed using the combination of 0.2mmol/L CuSO4 and 1mmol/L ascorbic acid in the presence or in the absence of 2 IU/mL EPO. Data are expressed as mean from 4 different erythrocyte preparations from the control population.
Kidney International  , DOI: ( /j x)
Copyright © 2005 International Society of Nephrology Terms and Conditions